Targeted immunotherapies for hematologic malignancies


Our focus

Our overall goal is to develop novel targeted immunotherapies for patients with hematologic malignancies. The group develops adoptive T cell therapies with native or engineered receptors and evaluates combinatorial strategies. The objective is to efficiently target tumor cells, mitigate immunosuppressive tumor microenvironment factors, favor tumor-targeted migration and longevity of transferred T cells, control potential toxicities, identify novel personalized targets, and move developments to the clinic.

Our projects

  • To redirect human T specificity to target hematologic malignancies by genetic engineering (chimeric antigen receptors, transgenic T cell receptors, others)
  • To develop combinatorial approaches to engineered T cell therapy targeting both the tumor cells and their microenvironment (e.g. engineer tumor-directed migration, resistance to immune inhibitory signals)
  • To engineer signaling switches in T cells that revert tumor-associated immune inhibitory signals.
  • To assess tumor microenvironment modulation upon adoptive transfer of engineered T cells, including omics and spatial technologies
  • To evaluate 3D culture systems to better model the tumor microenvironment in vitro and use them to evaluate transgenic T cell function
  • To identify immunogenic tumor neo-antigens in patients with hematologic malignancies and to isolate their neo-antigen specific TCRs for personalized medicine applications.
  • We apply principles from immunology, hematology, cancer and systems biology, use gene transfer and editing technologies to engineer T cells, and collaborate with experts in protein engineering, gene editing, proteomics/ peptidomics, immunomonitoring, bioinformatics, bioengineering, clinical hematology and immuno-oncology.



UNIL web teasers general.png


Follow us:  


Lausanne Oncology ARBER lab.png

Caroline ARBER
Associate Professor
Ludwig adjunct scientist

Laboratory C. Arber

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Ludwig Lausanne RGB-crop461x374.jpg (Print)

Phone +41 21 692 59 53



WEB medallions 150 x100-1 unsplash alexander shatov.png

Ch. des Boveresses 155 - CH-1066 Epalinges
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer ResearchUniversité de LausanneCentre Hospitalier Universitaire Vaudois (CHUV)